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Abstract
Incorporation of the clinically active deoxycytidine ana-
logue 20-C-cyano-20-deoxy-1-b-D-arabino-pentofuranosyl-
cytosine (CNDAC) into DNA generates single-strand breaks
that are subsequently converted to double-strand breaks
(DSB). Here, we investigated the cellular manifestations of
these breaks that link these mechanisms to cell death, and
we further tested the relevance of DNA repair pathways in
protection of cells against CNDAC damage. The present
investigations demonstrate that following exposure to
CNDAC and a wash into drug-free medium, chromosomal
aberrations, DNA strand breaks, and multinucleate cells
arose. These portended loss of viability and were dependent
upon exposure time, CNDAC concentration, and passage
through mitosis. Following a pulse incubation with
CNDAC, live cell imaging using GFP-tagged histone H2B
as a marker demonstrated a normal rate of progression to
mitosis, but a concentration-dependent delay in passage to a
second mitosis. Progression through mitosis was also
delayed and accompanied by formation of multinucleate
cells. CNDAC-treated cells lacking XPF-ERCC1 nuclease
function showed a 16-fold increase in chromosome aberra-
tions. Chromosomal damage in Rad51D-mutant cells
(homologous recombination repair deficient) were even
more severely affected with extensive aberrations. Rodent
or human Polq (POLQ) mutant cells, defective in Pol
q–mediated alternative end joining, did not show enhanced
cellular sensitivity to CNDAC. These findings are consistent
with formation of DSBs in the second S-phase following
exposure, resulting in chromosome aberrations, aberrant
mitoses, and subsequent apoptosis.
Introduction
The nucleoside analogue 20-C-cyano-20-deoxy-1-b-D-arabino-
pentofuranosyl-cytosine (CNDAC) and its orally bioavailable
prodrug sapacitabine are currently undergoing clinical trials
for acute myeloid leukemia (AML) and myelodysplastic
syndromes (1–4). CNDAC has a mechanism of action that is
distinct from other deoxycytidine analogs (5). After phosphor-
ylation to the triphosphate and its incorporation into DNA,
the instability of the analogue induces a b-elimination rear-
rangement that results in the transformation of the analogue to
CNddC, a de facto 30-terminus DNA chain terminator (6, 7). The
resulting single-strand breaks (SSB) have been shown to be
converted into double-strand breaks (DSB) during DNA repli-
cation in a subsequent S-phase (8). These consequences are
supported by evidence of chromosome damage.
The molecular mechanism(s) of action of CNDAC have been
investigated by employing cell lines process blocked 30 ends lead
to increased sensitivity to CNDAC. Exposure of cells with defec-
tive XPF-ERCC1 nuclease to CNDAC for one cell cycle decreased
the IC50 in clonogenic assays by 3- to 5-fold (9). In addition, the
viability of cells lacking tyrosyl-DNAphosphodiesterase 1 (TDP1)
was similarly sensitized to CNDAC, consistent with the conclu-
sion that it also can remove a CNddC-terminated DNA end (10).
In contrast, the viability of cells lacking either base excision repair
function or DNA mismatch repair was not changed from those
with intact repair pathways.
The nature of the DNA damage initially reported indicated the
presence of DSBs. Treatment of cells lacking any of several
enzymes (ATM, XRCC3, RAD51D, BRCA2) in the ATM-
dependent homologous recombination pathway (HR) with
CNDAC for two cell cycle times decreased IC50 for clonogenicity
by30- to 100-fold (8). Thefinding that the viability of cells lacking
nonhomologous end-joining (NHEJ) function was not dimin-
ished beyond that of NHEJ-competent cells supported the con-
clusion that HR repair of CNDAC-induced DSB is the primary
mechanism of cell death (8). However, an alternative end-joining
pathway, also known as microhomology-mediated end joining,
has recently emerged as an important repair mechanism com-
plementary to the classical NHEJ pathway (11). DNA polymerase
q (Pol q) is a key component involved in alternative end-joining
and has been shown to be synthetic lethal with the HR path-
way (12, 13). The possible contribution of this pathway to repair
of CNDAC-induced damage has not yet been reported.
At the subcellular level, CNDAC exposure gives rise to chro-
mosomal aberrations (14). However, it remains obscure as to
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how CNDAC-induced DSBs, manifested as chromosomal dam-
age, lead to cell death. In the current study, we focused on
CNDAC-caused DNA lesions at the chromosomal level. Chinese
hamster ovary (CHO) cell lines deficient in either XPF (a com-
ponent of the XPF-ERCC1nuclease) or RAD51D (a component of
the HR pathway) were investigated. In addition to chromosomal
aberrations, we observed that cells treated with CNDAC formed
multiple nuclei, a prominent feature associated with mitotic
catastrophe. To better characterize the events before, during and
after the aberrant mitosis, we used live cell imaging to track cell
fate in real time.
Materials and Methods
Materials
The nucleoside analogue CNDACwas synthesized as described
and generously provided by Professor A. Matsuda (University of
Sapporo, Hokkaido, Japan; refs. 15, 16). The following reagents
were purchased from Thermo Fisher Scientific: Karyomax Giemsa
stain stock solution (catalog no. #10092013); Gurr buffer solu-
tion tablets (catalog no. #10582013); Histomount mounting
solution (catalog no. #008030); OptiMEM I reduced serum
medium (catalog no. #31985062); Blasticidin S HCl solution
(catalog no. #A1113903). Sources of other reagents are listed as
follows: Accutase (catalog no. #07920) from Stemcell Technol-
ogies; pBOS-H2BGFP vector (catalog no. #559241) from BD
Pharmingen; FuGENE HD transfection reagent (catalog no.
#E23110) from Promega; protease inhibitor cocktail tablets (cat-
alog no. #04693159001) and phosphatase inhibitor cocktail
tablets (catalog no. #04906837001) from Roche.
Antibodies
mAbs to phospho-Ser1981 ATM (catalog no. #05-740) and
phospho-Ser139 H2AX (catalog no. #05-636) were purchased
from Upstate/Millipore. Rabbit mAb to DNA-PKcs (catalog no.
#ab32566) and polyclonal antibody to ATM (catalog no.
#ab17995) were from Abcam. Polyclonal antibody to H2AX
(catalog no. #GTX108272) was from GeneTex. a-Tubulin and
b-actin mAbs were from Sigma-Aldrich (catalog no. #T5168).
mAb to PARP (catalog no. #51-6639GR) was from BD Pharmin-
gen. mAb to caspase-3 (catalog no. #3004) was from BioVision,
and polyclonal antibody to cleaved caspase-3 (catalog no. #9661)
was from Cell Signaling Technology.
Cell lines
CHO lines AA8 [wild type (WT)] and UV41 (Xpfmutant) were
purchased from the ATCC. The AA8-derived Rad51D knockout
line, 51D1, and the Rad51D complemented line, 51D1.3 (17),
were gifts from Dr. L. Thompson (Lawrence Livermore National
Laboratory, Livermore, CA). All CHO lines were grown in aMEM
(free of ribonucleosides and deoxyribonucleosides) supplemen-
ted with 10% heat-inactivated FBS and GlutaMax. Mouse embry-
onicfibroblast (MEF) linesPolqþ/þ (55-5 Tag),Polqþ/ (55-7 Tag),
and Polq/ (55-6 Tag; ref. 11) were cultured in DMEM supple-
mented with 10% heat-inactivated FBS and GlutaMax. Human
osteosarcoma U2OS POLQþ/þ cell lines were used by RDW and
KT to generate two independent POLQ/ knockout clones F10
and G6. The U2OS cells were cultured in the samemedium as the
MEFs. POLQ knockout by frameshift was confirmed by genomic
DNA sequencing and reduced POLQmRNA level was verified by
qPCR (Supplementary Fig. S3C). POLQþ/þ, POLQ/, (F10) and
POLQ/ (G6) were stably transfected with shControl and
shDNA-PKcs, respectively. Knockdown of DNA-PKcs was con-
firmed by immunoblotting. The human lung cancer cell line
H460 was a gift from David G. Beer (University of Michigan,
Ann Arbor, MI). All human cell lines were authenticated using
short tandem repeatDNAfingerprinting by theCharacterizedCell
Line Core at the MD Anderson Cancer Center (Houston, TX). All
rodent andhuman cells were free ofMycoplasma, as certifiedby the
same core facility using the MycoAlert Kit from Lonza. Each line
was used in experiments for no more than 15 passages after
recovering from frozen seed stocks that were authenticated prior
to freezing.
Cell-cycle analysis
Adherent cells were detached with Accutase, washed with ice-
cold PBS (pH 7.4), and fixed in 70% ethanol for at least 1 hour on
ice or overnight at 4C. Fixed cells were washed with PBS and
incubated with 50 mg/mL propidium iodide (PI) and 2.5 mg/mL
DNase-free RNase (14). A Becton Dickinson FACSCalibur flow
cytometer with BDCellQuest Pro programwas used to determine
the DNA content in each sample by measuring the fluorescence
from at least 20,000 cells.
Apoptosis analysis
Detached cells were washed with PBS and resuspended in
100 mL of binding buffer with 5 mL of Cy5-conjugated Annexin
V (BD Pharmingen, catalog no. #559934). After 15-minute
incubation in the dark at room temperature, 400 mL of binding
buffer with 5 mL of 50 mg/mL PI was added to each sample.
At least 20,000 cells were analyzed using a BD FACSCalibur
flow cytometer with the CellQuest Pro software. Cells stained
positive for Annexin V (PI negative and positive) were consid-
ered apoptotic cells.
Cell growth rate analysis
Exponentially growing cells were plated in multiple 100-mm
dishes at 105/dish. At indicated times, duplicate dishes of cells
were detached using 0.05% trypsin–EDTA solution and subjected
to quantitation of total cell numbers using a Coulter Counter
(Beckman Coulter Life Sciences). The total number of cells (mean
of two dishes) were plotted as a function of time. Population
doubling time (PDT) of each cell line was computed using the
tool at http://www.doubling-time.com/compute_more.php.
Clonogenic survival assay
Adherent MEF or human U2OS cells, WT or Polq (or POLQ)
knockout, were seeded in 6-well plates one day before they were
exposed to a range of concentrations of drugs for 24 hours. Cells
were washed into drug-free medium and incubated for an addi-
tional 3 days (MEFs) or 6 days (U2OS lines) to form colonies.
Colonies in triplicate wells were fixed and stained with crystal
violet/ethanol and counted under a dissectingmicroscope (cutoff
 50 cells) or scored electronically (GelCount, OxfordOptronix).
Percent survival is expressed as mean  SD.
Cytogenetic analysis
Colcemid (100 ng/mL) was added to cell cultures before
harvesting. Mitotic spreads were prepared as described previous-
ly (14). A minimum of 50 metaphase spreads were analyzed for
each sample by the T.C. Hsu Molecular Cytogenetics Core at the
MD Anderson Cancer Center.
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Detection of multinucleate cells
CNDAC-treated AA8 cells were detached with Accutase, trans-
ferred onto slides using a Shandon Cytospin 3 cytocentrifuge
(700 rpm for 5 minutes at room temperature), and air dried
briefly. Cells were fixed in 70% ethanol at 4C for a minimum of
1 hour and air dried again. Giemsa stain solution was freshly
diluted inGurr buffer (1 tablet in 1 L ofwater, pH 6.8) to 4% (v/v)
and used for staining the cells on slides for 20 minutes at room
temperature. Cells were rinsed, air dried overnight, and mounted
with coverslips using Histomount mounting solution. Images of
cells in bright field were captured at randomly selected fields
under aNikon lightmicroscope (20objective lens) using a Sony
3CCD color video camera (model no. DXC-390, SimplePCI
software). For each treatment, nuclearmorphologyof aminimum
of 400 cells was analyzed and categorized according to the
samples in Supplementary Fig. S4. Qualitative images were taken
using 40 and 100 oil lenses.
Immunoblotting
Cell lysates, prepared by sonication in RIPA buffer supplemen-
ted with protease inhibitor and phosphatase inhibitor cocktail
tablets, were loaded on Bis-Tris 4% to 12% polyacrylamide
gradient gels (Bio-Rad) and transferred onto nitrocellulose mem-
branes (0.22 mm) as described previously (14). Immunoblots
were visualized and target bands were quantitated by Li-Cor
Odyssey Version 4.0 software.
Single-cell gel electrophoresis (comet assay)
DNA strand breaks were detected using single-cell gel elec-
trophoresis under both neutral pH and alkaline conditions
using CometAssay Electrophoresis System II (Trevigen, catalog
no. #4250-050-ES). After electrophoresis, cells embedded
in low-melting agarose (comets) were fixed with 70% ethanol
and stained with SYBR Gold (Thermo Fisher Scientific, catalog
no. #S-11494). Images of comets in random fields were cap-
tured under Olympus IX70 inverted fluorescence microscope
using Olympus DP70 CCD camera and 4 objective, and
subjected to quantitation using Comet Assay IV software
(Instem). At least 200 cells per treatment condition were
scored. An increase in Olive tail moment from a neutral comet
assay was used as a readout for DSBs, whereas that from an
alkaline comet assay for the sum of SSBs and DSBs. Additional
images were taken using 10 or 20 objectives to feature more
details of comets.
Stable expression of histone H2B-GFP
AA8 cells were transfected with pBOS-H2BGFP vector (18)
using FuGENE transfection reagent in OptiMEM I. Cells
stably expressing H2B-GFP fusion proteins were selected by
addition of 5 mg/mL blasticidin in complete medium over a
period of 2 to 3 weeks. Cultures were monitored daily under
Olympus IX70 inverted fluorescent microscope and imaged
as needed using 20 objective at both fluorescent and bright
light channels. GFP-positive cells were isolated on BD FACS
Aria IIu cell sorter and two populations, GPFþ high and GFPþ
low, were collected and propagated separately. No significant
difference in growth rate, based on size of colonies formed, was
observed for the two populations. The GFPþ high cells were
used for live cell imaging. H460 cells were stably transfected
with pBOS-H2BGFP vector following the same procedure
as AA8.
Time-lapse video microscopy
AA8/H2B-GFP cells were grown in chamber slides overnight
and set up in an Olympus live cell imaging station enclosed by a
micro cell incubator with humidified air and active controllers for
temperature (37C) and CO2 (5%). HEPES (10 mmol/L) was
supplemented in complete medium to increase pH buffering
capacity. A 20 relief phase contrast objective was used on the
Olympusmicroscope. Multiple positions were randomly selected
with well isolated cells at a low density and the objective was
adjusted to focus for each position. Cells were exposed toCNDAC
at 0.5, 1, and 10 mmol/L, respectively, for 6 hours before washout.
The microscope and connected computer were programed to
capture images of both GFP fluorescence and bright field every
15 minutes after CNDAC washout. The live cell imaging was
carried out for 114 hours after the initial 63 hours. Meta Morph
Advanced image analysis software was applied to compile images
into time-lapse videos and perform subsequent analyses.
Statistical analysis
For the quantitation of chromosomal aberrations, tail moment
of comets, and the live cell imaging, intergroup comparisons of
endpoints in response to various treatments were made using a t
test with two-tailed distribution and two-sample unequal vari-
ance in Excel.
Results
Deficiency in XPF results in greater levels of chromosomal
aberrations induced by CNDAC
Cellular response to CNDAC is concentration- and time-
dependent (14). We postulated that processing or DNA replica-
tion across the unrepaired nicks would generate DSBs, which in
turn would lead to the death of cells by yet undefinedmechanism
(s). To address this, cytogenetic endpoints were used to charac-
terize the consequences of deficiencies in specific DNA repair
mechanisms. Metaphase chromosomal aberrations (including
breaks and gaps) were compared in the WT AA8 line and its
mutant UV41, which lacks XPF (19, 20). The cell lines were
continuously treated with CNDAC at 1 mmol/L, which is a non-
arresting concentration for both lines after one cell cycle (15–16
hours). However, after drug exposure for 2 cell cycles (30 hours),
the mutant line was delayed in transiting the second G2, whereas
this was not observed for the WT cells (Supplementary Fig. S1).
Therefore, the addition of colcemidwas scheduled earlier than for
WT cells to ensure prolonged incubation time to enrich the
number of mitotic cells for analysis. In cells lacking XPF, chro-
mosomal aberrations increased from an average of 0.4/meta-
phase to 0.9/metaphase after one cell cycle treatment with 1
mmol/L CNDAC, and to 5.6/metaphase after two cell cycles, that
is, 30 hours (Fig. 1A, gray bars, n  60, P < 0.01; Fig. 1B).
Chromosomal aberrations in the WT cells did not increase as
dramatically, from 0.05/metaphase to 0.2/metaphase after two
cell cycles (Fig. 1A, black bars, n  55, P < 0.05). These data
support the interpretation that SSBs induced by CNDAC in the
first S-phase can be converted into DSBs during the second S-
phase when replication forks encounter unrepaired SSBs and that
an XPF-dependent mechanism provides protection against gen-
eration of DSBs.
The increase in chromosomal aberrations after CNDAC expo-
sure, regardless of length of time, was greater in UV41 cells
compared to the WT. The mean values of chromosomal
Cell Death Mechanisms by CNDAC
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Increased chromosomal aberrations in XPF-deficient cells after CNDAC treatment. Wild-type AA8 cells and UV41 (Xpfmutant) cells were treated with 1 mmol/L
CNDAC for 15 and 30 hours. A,Quantitative plot of chromosomal aberrations (gaps and breaks) in bothWT and XPF-mutant cell lines. Bars showmean SD
values of numbers of chromosomal aberrations per metaphase. B, Representative metaphase image of Xpf-mutant cells treated with 1 mmol/L CNDAC for
30 hours. An arrow indicates a gap (short) or a break (long). C, Bar plot showing distribution of chromosomal aberrations in both cell lines. More than 2
chromosomal aberrations/metaphase were not detected inWT control or CNDAC-treated cells. D, Bar plot showing comet tail moment of Xpf-mutant cells
treated with 1 mmol/L CNDAC for 15 and 30 hours, respectively, from comet assays under neutral and alkaline conditions. For each treatment, 200 cells were
quantified and the mean SD values of tail moment were presented. E, Immunoblotting of phospho- and total ATM and H2AX inWT and Xpf-mutant cells
treated with CNDAC at indicated concentrations for 15 and 30 hours. The ratios of phospho- to total proteins were calculated and normalized to those of
corresponding controls. Each cell line was exposed to 50 J/m2 UV irradiation and incubated for 30 minutes before being collected to use as a positive control for
the phosphorylation of ATM or H2AX. b-Actin was used as a loading control.
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aberrations increased 6-fold in WT and >6-fold in XPF-mutant
cells after two PDTs compared with those treated for only
one PDT (Fig. 1A, 30- vs. 15-hour bars). More impressively,
the average number of chromosomal aberrations increased 16-
fold after two cell cycles in the mutant (5.6 aberrations/meta-
phase) compared with a 5-fold change in the WT cells (0.22/
metaphase, Fig. 1A). The distribution of chromosomal aberra-
tion frequencies was also distinct between the two lines. Sixteen
percent of WT cells treated with CNDAC for two PDTs had 1 to
2 chromosomal aberrations, and no cells had more than 2
aberrations per metaphase. In contrast, 42%, 30%, and 12% of
XPF-mutant cells exhibited 3–5, 6–10, and 10–20 aberrations
per metaphase, respectively (Fig. 1C). These results are consis-
tent with a decrease in clonogenic survival in XPF-deficient cells
after CNDAC exposure (9), indicating that XPF contributes to
the repair of CNDAC-induced damage.
To provide direct evidence for the presence of DNA strand
breaks, comet assays were performed in XPF-deficient and WT
cells. In XPF-mutant cells, both neutral and alkaline comet assays
demonstrated significant elevation in tail moments after CNDAC
incubation (Fig. 1D). Under a neutral condition, the tail moment
of control cells increased from 4.06  2.72 to 6.12  4.47 after
incubation with 1 mmol/L CNDAC for 15 hours, and further to
12.61 6.92 at 30 hours (Fig. 1D; Supplementary Fig. S2A). This
result parallels the change in chromosomal aberrations after
CNDAC treatment (Fig. 1A). The minor increase in either comets
or chromosomal aberrations after 15-hour CNDAC exposure
could be interpreted as the conversion of endogenous SSBs into
DSBs upon CNDAC incorporation during the first cell cycle. Both
comets and chromosomal aberrations soared after 30-hr incuba-
tion with CNDAC, indicating an increase in DSBs after a second
cell cycle. The comet assay under an alkaline condition revealed a
similar change in comets but to a greater extent. The tail moment
of untreated UV41 cells was 4.32  4.36, while the CNDAC-
treated cells presented a tail moment of 14.63 6.44 at 15 hours
and 41.2 9.28 at 30 hours, respectively (Fig. 1D; Supplementary
Fig. S2A). Furthermore, the phosphorylation of ATM on Ser1981
andH2AX on Ser139 (g-H2AX) increased slightly at 15 hours and
to a greater extent after 30 hours of CNDAC treatment (Fig. 1E,
right). Together, the comet assays and immunoblot results in XPF-
deficient cells demonstrated that CNDAC-induced SSBs could be
transformed into DSBs after a second S-phase. Although the WT
AA8 cells presented increased levels of phosphorylated ATM and
H2AX in a similar pattern to that found in the XPF mutants
(Fig. 1E, left), comet tails were not discernible under alkaline
condition when AA8 cells were exposed to 2 mmol/L CNDAC for
30 hours (2 cycles). However, comet tail legnth greatly increased
after 10 mmol/L CNDAC (Supplementary Fig. S2B and S2C). The
tail moments of AA8 cells were 7.2  6.4 for the control, 52.9 
7.0 after 15-hour treatment and 75.5  10.7 after 30-hour
treatment.
Rad51D-defective cells present severe chromosomal damage in
response to CNDAC
HR is themain pathway to repair DSBs induced byCNDAC (8).
Here, we compared the cytogenetic changes after CNDAC treat-
ment in cells deficient in RAD51D, a component of the HR
mechanism (21), and cells complemented with RAD51D. In the
absence of CNDAC exposure, RAD51D-deficient cells had an
elevated background of chromosome alterations. Seventy-three
percent had no apparent spontaneous chromosomal alteration;
23.8% and 1.6% presented 1–2 and 3–4 breaks per metaphase,
respectively; the remaining 1.6%had fusions (Fig. 2A, gray bars, n
¼ 63). In untreated RAD51D complemented cells, no aberrations
were detected in 90% of the population, and 1–2 aberrations per
metaphase were seen in the remainder of cells (Fig. 2A, black bars,
n¼ 80). These data show a baseline genetic instability that can be
attributed to deficiency in RAD51D.
A larger portion of the RAD51D complemented cells
(Fig. 2A, 19%, n ¼ 99) bore 1–2 chromosomal breaks, when
exposed to 1 mmol/L CNDAC for two PDTs, than those exposed
to CNDAC for only one population doubling time (Fig. 2A,
8.3%, n ¼ 72). At both times, a minor portion of cells treated
with CNDAC (1%–2%) had more than 2 breaks per metaphase.
Notably, after two cell cycles, 99% of all metaphases from
CNDAC-treated RAD51D complemented cells could be ana-
lyzed, including 78% metaphases free of aberration and only
1% was unscorable (Fig. 2A, n ¼ 99). In contrast, 76% of the
metaphases in RAD51D-deficient cells exposed to CNDAC for
two PDTs had severe chromosomal damage and therefore were
unscorable for individual aberrations (Fig. 2B). Radial forma-
tion was apparent in some chromosomes, consistent with a
defect in the HR function. Another 9% and 2% presented 1–2
breaks and 3–4 breaks per metaphase, respectively. Only 13%
of the population were free of chromosomal aberrations
(Fig. 2A, n ¼ 106). As for the RAD51D-deficient cells treated
with CNDAC for one population doubling time, 28% and 3%
had 1–2 breaks and 3–4 breaks per metaphase, respectively;
1.5% had fusions; and the rest were free of chromosomal
aberration (Fig. 2A, n ¼ 68). The RAD51D-deficient cells
showed fewer aberrations after one cell cycle than that after
two cell cycles. This is consistent with results from the RAD51D
complemented cells and the paired XPF cells as well, further
supporting the hypothesis that DSBs are formed during a
second cell cycle. Importantly, the much greater extent of
chromosome damage in cells exposed to CNDAC for a second
S-phase relative to that in cells treated for only a single cell cycle
is consistent with the much greater clonogenic sensitivity
caused by defects in homologous recombination repair than
by a defect in XPF-ERCC1 nuclease (8, 9).
Lack of DNA polymerase q does not confer sensitivity to
CNDAC
The role of the alternative DNA end-joining pathway in the
repair of CNDAC-induced damage, if any, has not be defined. We
compared the clonogenic survival rate of WT cells with a MEF
line in which Pol q, the product of the Polq gene, had been
knocked out (11). The clonogenic survival of MEF cells that were
either proficient or deficient in Pol q was similar (Fig. 3A, P ¼
0.051). The PDTs of MEFs with different Polq status were
15.9 hours for Polqþ/þ, 19.8 hours for Polqþ/, and 25.5 hours
for Polq/ (Supplementary Fig. S3A). Consistent with the above
observations, clonogenic assays of human U2OS POLQþ/þ and
POLQ/ cells transfected with shControl were similarly sensitive
to CNDAC (Fig. 3B, left), while POLQ/ cells were sensitized
about 2-fold to the comparator DNA strand-breaking agent,
bleomycin (Fig. 3B, right). Previous investigations demonstrated
that cells lacking the classical NHEJ component, DNA-PKcs, were
not sensitized to CNDAC (8). Therefore, we investigated the
CNDAC sensitivity of cells defective in both classical NHEJ and
alternative end-joining.U2OSPOLQþ/þ andPOLQ/ cells stably
transfected with shDNA-PKcs showed similar sensitivity to each
Cell Death Mechanisms by CNDAC
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agent in clonogenicity assays (Fig. 3C), although the PDT
of POLQþ/þ cells (27.0 hours) was somewhat more rapid
relative to that of POLQ/ cells (31.8 hours). However, the
PDTs were further prolonged in DNA-PKcs knockdown
POLQþ/þ (41.2 hours) and POLQ/ (46.1 hours) cells (Supple-
mentary Fig. S3B). Therefore, depletion of Pol q and/orDNA-PKcs
inU2OS cellsmay hinder cell proliferation. Thus, similar findings
in the two cell lines compromised for Pol q function indicates that
the alternative end-joining pathway is dispensable for repair of
CNDAC-induced DSBs.
Exposure to CNDAC induces formation of multinucleate cells
CHO cells manifested metaphases with chromosomal aber-
rations in response to CNDAC to a greater extent after two PDTs
and in the absence of key components of DNA damage repair
pathways, such as XPF or RAD51D. To further study the con-
sequences of entering mitosis with chromosomal instability,
we analyzed the incidence of multinucleate formation follow-
ing exposure to AA8 cells to CNDAC 24 hours. Because only WT
cells were used in the study, a higher concentration of CNDAC
(10 mmol/L, causing G2 arrest) was tested in addition to two
lower and nonarresting concentrations (0.5 and 1 mmol/L).
Cells incubated with CNDAC for 24 hours were released into
drug-free medium and analyzed for effects on their inability to
complete normal mitosis as indicated by multinucleate forma-
tion after drug washout. Atypical interphase cells with more
than a single nucleus were collectively counted as multinucle-
ate (Supplementary Fig. S4C–S4G). The percentage of such cells
increased in a CNDAC concentration-dependent fashion. Nota-
bly, among cells exposed to 1 mmol/L CNDAC, multinucleation
was identified in approximately 22% and 13% of the popula-
tion 24 and 48 hours after drug washout, respectively (Fig. 4A
and B II). It was more evident that about 24% and 34% of 10
mmol/L CNDAC-treated cells presented multinucleation at 24
and 48 hours, respectively (Fig. 4A and B III-IV). When cells
were exposed to CNDAC for 15 hours and then released in
drug-free medium, a substantial increase in multinucleation
was only observed in cells treated with 10 mmol/L CNDAC, not
those with 0.5 or 1 mmol/L CNDAC (Supplementary Table S1).
This is likely because longer drug-exposure time allows for
more CNDAC incorporation in the DNA of all cells. Neverthe-
less, in both 24- and 15-hour schedules, multinucleation was
not evident until after two PDTs, suggesting that the abnormal
nuclear alterations occur after a second mitosis.
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Diverse cytogenetic changes in cells
lacking RAD51D after CNDAC
exposure. Wild-type AA8 cells and
RAD51D-deficient cells (51D1) were
treated with 1 mmol/L CNDAC for 15
and 30 hours, respectively.A, Bar plot
showing percentage of cells with
various types of chromosomal
aberrations, including breaks, fusions,
and unscorable metaphases, in both
cell lines. B, Representative images of
severe chromosomal damage induced
by CNDAC (1 mmol/L, 30 hours) in
RAD51D-deficient cells, 40 objective
used.
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U2OS POLQ−/− (G6) shControl
U2OS POLQ−/− (F10) shControl
U2OS POLQ+/+ shControl
IC50
CNDAC, nmol/L Bleomycin, µg/mL
U2OS POLQ+/+ shControl 244 5.14
U2OS POLQ−/−
−/−
(F10) shControl 200 (ns) 2.41 (ns)

























CNDAC, nmol/L Bleomycin, mg/mL
U2OS POLQ+/+
shDNA-PKcs 169 1.0
U2OS POLQ−/− (F10) 
shDNA-PKcs 176 (ns) 1.3 (ns)
IC50, nmol/L
Polq+/+ MEF 546



































ns: P > 0.05 vs. Polq+/+
ns: P > 0.05 vs. POLQ +/+
ns: P > 0.05 vs. POLQ+/+
Figure 3.
Clonogenic survival of human andmouse cell lines in response to CNDAC is independent of the status of DNA polymerase q (POLQ or Polq) in the alternative end
joining pathway.A, Polqþ/þ and Polq/MEF lines were treated with CNDAC for 24 hours and allowed to form colonies in the absence of CNDAC. B, POLQþ/þ
and POLQ/ (clones F10 and G6) human osteosarcoma U2OS lines stably expressing shControl were treated with varying concentrations of CNDAC or
bleomycin for 24 hours in colony formation assays. C, POLQþ/þ and POLQ/ U2OS lines stably expressing shDNA-PKcs were treated with CNDAC or bleomycin
for 24 hours before washout for colony formation. Representative plots of percentage of cell survival as a function of drug concentration are shown. IC50 values
of each agent are listed in the inserted table. "ns" stands for not significant. D, Immunoblotting of DNA-PKcs in POLQþ/þ and POLQ/ (clones F10 and G6) U2OS
cells transfected with shControl and shDNA-PKcs, respectively. The asterisk indicates nonspecific proteins recognized by the antibody. Tubulin was used as a
loading control.
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Treatment No. of cells quantitated
% 
Interphase
%   
Mitotic





24 h 626 96.0 3.2 0.8 0
48 h 560 96.1 3.4 0.5 0
72 h 926 89.7 1.3 0.6 8.3
CNDAC 0.5 µmol/L 24 h → 
No wash 858 95.9 3.1 0.8 0.1
Wash →  24 h 1,235 90.8 2.4 6.2 0.6
Wash →  48 h 947 86.9 1.4 4.8 7.0
CNDAC 1 µmol/L 24 h →
No wash 669 95.2 2.2 2.2 0.3
Wash →  24 h 810 72.1 4.0 22.1 1.85
Wash →  48 h 832 78.6 1.3 12.7 7.3
CNDAC 10 µmol/L 24 h →
No wash 605 96.9 0.5 2.6 0
Wash → 24 h 731 68.0 0 23.5 8.5





24 h after washout of CNDAC (10 µmol/L 24 h)




Postmitosis nuclear alterations after washout of CNDAC: increase in multinucleated cells. AA8 cells were incubated with 0.5, 1, and 10 mmol/L CNDAC for
24 hours before washout and release into drug-free medium. Cells were detached without washing out of CNDAC, or 24 and 48 hours following washout. Cells
were collected onto slides by cytospin, fixed, and stained with Giemsa. Nuclear morphologies of at least 600 cells were analyzed and categorized into interphase,
mitotic, multinucleate, and unscorable. A,Quantitation of nuclear morphologies in cells following CNDAC washout. B, Representative images of Giemsa-stained
AA8 cells. I, Control; II, 24 hours after washout of CNDAC (1 mmol/L 24 hours); III–IV, 24 hours after washout of CNDAC (10 mmol/L 24 hours). I–III, 40 objective;
IV, 100 objective. No., number.
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Live cell imaging reveals a prolonged second interphase,
aberrant mitosis, and formation of multinucleate cells after
CNDAC
Multi-nucleation, a hallmark of mitotic catastrophe, has
been found in a significant portion of CNDAC-treated AA8
cells. We used time-lapse video microscopy to test the hypoth-
esis that exposure of S-phase cells CNDAC causes mitotic
catastrophe prior to cell death. The fate of AA8 cells stably
transfected with a construct expressing H2B-GFP fusion protein
after a 6-hour pulse 0.5, 1.0, and 10 mmol/L of CNDAC,
respectively, was tracked followed by drug washout. Image
capture was started immediately after wash. Cells entering the
first mitosis within 5 hours after washout were presumed to
have had CNDAC incorporation into DNA and therefore were
eligible for analysis (Supplementary Fig. S5A). There was no
difference in the duration of first mitosis among all three
treatments and control (Fig. 5A–D, orange bars; Fig. 5E, n 
24, P > 0.05). However, the duration of second mitosis was
significantly prolonged in a CNDAC concentration-dependent
manner in all treatments compared with control (Fig. 5, red
bars; Fig. 5E, n  37, P < 0.05–0.001). The interval from
the beginning of the first mitosis to the second was also
prolonged markedly in 1 and 10 mmol/L CNDAC-treated sam-
ples (Fig. 5E, P < 0.01–0.001). A similar trend was observed in a
H2B-GFP transfected H460 lung cancer cells following wash
out of CNDAC (0.4 mmol/L, 8-hour exposure). In this case,
because of the longer cell cycle time, cells entering first mitosis
within 7.5 hours after wash were quantitated (Supplementary
Fig. S5B). There was significant increase in the duration
of second mitosis and in the interval between the first and
second mitoses (Supplementary Fig. S6, n  38, P < 0.01 and P
< 0.001, respectively). Thus, cell-cycle progression was slowed
due to CNDAC-induced DNA damage, especially when DSBs
are expected to arise.
Notably, large numbers of CNDAC-treated AA8 cells were
delayed in completion of the second mitosis, which was abnor-
mal, and associatedwith the formation ofmultinucleate daughter
cells (Fig. 5, blue bars). For cells exposed to 10 mmol/L CNDAC,
multinucleation was found to be coupled to the second mitosis
and followed by the onset of apoptosis in 18 out of 25 cells
tracked. The snapshots in Fig. 6 and video clip in Supplementary
Fig. S7 illustrate how one of those cells (#10) went through a
seemingly normal, first mitosis (Fig. 6A), and its two daughter
cells progressed through aberrant second mitoses followed by
multinucleate formation and cell death (Fig. 6B).Multinucleation
was also apparent in cells treated with different schedules of
CNDAC exposure and washout (Supplementary Fig. S8). Thus,
MM formation was frequently coupled with or followed by onset
of apoptosis. Together the results from static nuclei (stained with
Giemsa) and live cell imaging indicate that CNDAC-induced
DSBs, which, if not repaired, trigger cells to undergo aberrant
mitoses resulting in gross nuclear alterations. Multinucleation
precedes eventual cell death through apoptosis, which was sub-
stantiated by cleavage of caspase-3 and PARP (Fig. 6C), as well as
positive staining of Annexin V (Fig. 6D) after CNDAC washout.
All the readouts showed concentration- and time-dependency.
Discussion
This study aimed at defining the mechanism by which
CNDAC-induced DSBs lead to cell death. We used cytogenetic
approaches to compare CNDAC-caused chromosomal damage
in CHO cells proficient and deficient in XPF-ERCC1 nuclease.
The increase in chromosomal aberrations after CNDAC expo-
sure for an additional population doubling time (from one cell
cycle to two cell cycles), regardless of XPF status, has provided
direct cytogenetic evidence for conversion of CNDAC-induced
SSBs into DSBs during DNA replication. Spontaneous chromo-
somal alterations in XPF-deficient cells were 7.6-fold greater
than those in WT cells (Fig. 1A), indicating genetic instability
conferred by XPF deficiency. The fold increase in chromosomal
aberrations after CNDAC treatment was greater in Xpf-mutant
than in WT cells, underlining the importance of XPF in repair-
ing initial DNA damage caused by CNDAC. The XPF-ERCC1
endonuclease is multifunctional. It is not only essential for the
NER pathway, but also for processing some blocked 30 DNA
ends, and for completing HR initiated by the Fanconi anemia
pathway (19, 22, 23). XPF (ERCC4) has been identified as a
Fanconi anemia factor, FANCQ (24). XPF-ERCC1 participates
in the repair of interstrand crosslinks (ICL) by unhooking the
crosslinks in concert with FANCD2 and FANCP/SLX4 (25). The
resulting intermediate after resection is further processed by
HR. Although both ERCC1 and XPF-mutant cells are sensitized
by CNDAC (2.6- and 4.6-fold sensitization, respectively; ref. 9),
we focused on XPF deficiency in the cytogenetic analysis and
comet assay in the current study. In addition, the XPF-ERCC1
nuclease has been reported to facilitate Ku86-independent
end joining of DSBs in yeast and mouse and human fibro-
blasts (26). Because XPF-ERCC1 can act to remove some blocks
from the 30 ends of DNA (such as 30 deoxyribose-phosphate
and 30phosphoglycolate; ref. 27), it is likely that the enzyme
may perform a similar reaction to excise CNddC, the de facto
chain terminating lesion generated by b-elimination after
incorporation of a deoxynucleotide following CNDACMP at
the 30 terminus of the DNA (6).
Thus, it is likely that XPF-ERCC1 nuclease contributes to the
repair of the SSB caused by incorporation of CNDAC nucleotide
into DNA. We have postulated that failure to repair nicked DNA
may result in formation of a one-ended DSB upon a subsequent
DNA replication cycle. Direct evidence for this was previously
obtained by double labeling the DNA of ML-1 cells with a brief
pulse of CNDAC and IdUrd (to mark the first S-phase) and
followed by washing and addition of CldUrd before the second
S-phase (8). Time-course flow cytometry demonstrated that entry
of double positive cells into a second S-phase was concordant
with DSB formation measured by pulse-field gel electrophoresis.
The present studies are consistent with these findings in that they
provide additional evidence of chromosome aberrations andDSB
formation in the comet assay after two population-doubling
times.
Besides the paired XPF cell lines, we chose to investigate
cytogenetic alterations in RAD51D-deficient and proficient cells
after CNDAC treatment as an indication for HR in the DNA
damage repair processes. RAD51D mutations increase the risks
for women to develop ovarian cancer (28, 29). Similar to XPF,
deficiency in RAD51D renders genetic instability in that sponta-
neous chromosomal aberrations were more pronounced in AA8-
derived cells lacking Rad51D (27% of the cell population) com-
pared to cells complemented with Rad51D (10%, Fig. 2A). Both
lines showed minimal cytogenetic changes (<4%) after one cell-
cycle exposure to CNDAC, consistent with the timing of DSB
induction by CNDAC after a second S-phase. After exposure for
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Treatment 1st Mitosis 2nd Mitosis 1st 2nd Mitosis




No. of daughter 
cells tracked Duration (min) Time (h)
Control 24 51.9 10.8 37 52.3 12.1 22.6 5.0
0.5 µmol/L CNDAC 27 47.8 8.4 49 58.5 12.7 * 24.6 6.9
1 µmol/L CNDAC 28 53 7.6 44 69.9 20.7 ** 29.5 7.8 **
10 µmol/L CNDAC 25 57.0 15.0 40 200.3 58.5 *** 66.5 14.0 ***
* P < 0.05; ** P < 0.01; *** P < 0.001
E
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Evidence from time-lapse videomicroscopy for CNDAC-triggered cell death through mitotic catastrophe. AA8/H2B-GFP cells were treated with 0.5, 1, and 10
mmol/L CNDAC, respectively, for 6 hours before release into drug-free medium. Cells were monitored for approximately 5 days (114 hours) after washout. A
minimum of 24 cells entering mitosis within the beginning 20 frames, equivalent to 5 hours, were analyzed. Contingency bar plots of control cells (A) and
CNDAC-treated cells, 0.5 mmol/L (B), 1 mmol/L (C), and 10 mmol/L (D), are shown. Color bars represent the first to third interphases, the first to third mitoses, and
the phases of multinucleate formation and apoptosis, respectively. D, The asterisk symbol () indicates the particular daughter cells tracked in Fig. 6.
E,Quantitation and statistical analysis of time-lapse video microscopy: duration of mitoses and intervals between the first and secondmitoses after CNDAC
washout. No., number.
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Evidence from time-lapse videomicroscopy for CNDAC-triggered cell death through mitotic catastrophe. Snapshots of representative AA8 cells undergoing
aberrant mitosis (AM), multinucleate formation (MN), and apoptosis (AP) are shown. A, Fluorescent (GFP) image and its overlay with brightfield of the particular
cell tracked (#10 in Fig. 4D), taken 3.25 hours after CNDACwashout (Frame 13). B, Fluorescent images of the two daughter cells (#10A and #10B in Fig. 5D) and
corresponding overlays with bright field, taken at indicated frames and equivalent times. C, Immunoblotting of PARP and caspase-3, both in noncleaved and
cleaved forms, in AA8 cells washed 24 and 48 hours, respectively, after incubation with 1 and 2 mmol/L CNDAC for 15 hours. b-Actin was used as a loading control.
D, AA8 cells, treated as in C and incubated for 50 hours after CNDAC washout, were subjected to staining with Annexin V and propidium iodide (PI), followed by
detection with flow cytometry. Percentage of Annexin V positively stained population was indicated for each treatment.
Cell Death Mechanisms by CNDAC
www.aacrjournals.org Mol Cancer Ther; 18(12) December 2019 2293
on January 28, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Published OnlineFirst September 9, 2019; DOI: 10.1158/1535-7163.MCT-18-1380 
two cell cycles, the vast majority of RAD51D repleted cells (99%)
could be analyzed, whereas only a minor portion of RAD51D-
deficient cells (24%) were scorable, as most cells had extensive
chromosome damage (Fig. 2A). This further highlighted the
significance of RAD51D and the HR pathway in repair of
CNDAC-induced DSBs. The finding that cells lacking HR com-
ponents such as RAD51D cause significantly more chromosomal
aberrations and greater clonogenic sensitization to CNDAC than
XPF mutant cells, supports the conclusion that the chromosomal
alterations inXPFdeficient cells in response toCNDACaremainly
due to an HR-independent function of XPF-ERCC1.
Investigations with the Polq (or POLQ) knockout cell lines
indicated that the absence of Pol q function (30) does not
sensitize cells to CNDAC as measured by clonogenic survival
(Fig. 3; refs. 6, 31). Thus, it is unlikely that the alternative DNA
end-joining pathway has a crucial role in repair of CNDAC-
induced DSBs. Considering that deficiency in the classical NHEJ
pathway (deficiency in either DNA-PKcs or Ku80) does not
confer sensitivity to CNDAC, homologous recombination is
indeed the major mechanism for the repair of CNDAC-induced
DSBs (8).
Furthermore, we employed a traditional method, Giemsa
staining of AA8 cells treatedwith and thenwashedout of CNDAC,
to demonstrate the presence of multinucleate cells, which is
indicative of aberrant mitosis and characteristic of mitotic catas-
trophe (32). To detect relatively low levels of DNA damage in
repair competent cells, we treated cells with lesser concentrations
of CNDAC (0.5 and 1 mmol/L) and a greater concentration (10
mmol/L) that delayed cell-cycle progression. The percentage of
multi-nucleated cells was dependent upon both CNDAC concen-
tration and length of exposure time. Interestingly, multinucleate
cells became discernible only after two PDTs, highlighting that a
second mitosis is needed to enable the aberrant nuclear altera-
tions to occur and accumulate.
Finally, we exploited time-lapse video microscopy to better
observe cells in real time and verify mitotic catastrophe occur-
rence after CNDAC exposure and washout. The GFP-tagged
histone H2B stable expressing system was used to monitor
long-term dynamics of nuclei and chromosomes without
compromising their structures (33). Live cell imaging of two
cell lines of distinct origins demonstrated that conditions that
cause CNDAC-induced DSBs trigger cells to undergo an extend-
ed interphase followed by a prolonged second mitosis, coupled
with multinucleation and subsequent apoptosis. Such a process
characterizes mitotic catastrophe, which is visualized by the
multinucleate formation after an aberrant attempt at mitosis,
and is regarded as an oncosuppressive process for maintaining
genomic stability by leading to apoptosis, senescence, or necro-
sis (34). Active cancer therapeutics that damage DNA integrity
or interfere with mitotic processes are known to induce mitotic
catastrophe (35). The demonstration of multinucleate cells
following CNDAC treatment suggests the possibility that this
may serve as a pharmacodynamic indicator in clinical trials.
This possibility may be evaluated in clinical trials of the
parenteral formulation of CNDAC (as DFP-10917) or of sapa-
citabine, the orally bioavailable prodrug of CNDAC, which are
undergoing clinical trials in AML and myelodysplastic syn-
dromes with encouraging outcomes (2–4, 36). Furthermore,
sapacitabine has also shown antitumor activities in multiple
solid tumor types lacking BRCA1 or BRCA2 (37, 38), confirm-
ing our findings in hamster and human cell lines (8, 39).
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